Last Friday, Lexaria Bioscience Corp. (NASDAQ: LEXX) had outstanding stock performance for the third day in a row, helped by encouraging findings from a recent pilot clinical research. The company’s stock increased by 21.05% to close at $3.91 after rising by more than 10% the day before.
Lexaria Shared Clinical Research Success
The results of Lexaria Bioscience’s human pilot study #2, GLP-1-H24-2, which examined the pharmacokinetics and tolerability of their Rybelsus capsules processed using DehydraTECH, were made public. Designed to administer the GLP-1 medication semaglutide, these capsules showed better tolerability than the Rybelsus tablets that are sold commercially.
Notably, none of the nine participants who consumed the DehydraTECH-processed Rybelsus capsules experienced adverse events. In contrast, six of the nine participants who took the standard Rybelsus tablets reported mild adverse effects.
Comparative Analysis of Tolerability
The study also included an evaluation of the DehydraTECH-processed Rybelsus in a dissolvable oral format. Five of the six individuals who experienced mild adverse events from the Rybelsus tablets also reported similar issues with the dissolvable format.
These findings are consistent with those from Lexaria’s prior human pilot study #1, GLP-1-H24-1, which had also shown that DehydraTECH-processed Rybelsus capsules were generally better tolerated than Rybelsus tablets, which had induced moderate nausea or diarrhea.
LEXX Planning Future Implications And Ongoing Research
The results suggest a potential for decreased adverse events with DehydraTECH-processed Rybelsus capsules compared to the commercially available tablets. This is particularly notable given that Rybelsus is known to produce higher incidences of side effects compared to the injectable product Ozempic, which outsells it significantly.
If further clinical testing confirms these findings, DehydraTECH’s enhanced oral tolerability could potentially drive greater adoption of oral GLP-1 therapies. Additionally, the study’s third arm, which assessed the DehydraTECH-processed Rybelsus as a dissolvable in-mouth tablet, showed promising results from a conceptual standpoint.
Analysis of blood samples from the 20-minute to 24-hour marks revealed that the DehydraTECH-processed Rybelsus mouth-melt had a 32.3% and 106.9% higher systemic absorption rate compared to the standard Rybelsus tablet, respectively.
